Subscribe
Subscribe
Picture of BioVox

BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is powered by Biovia: the health innovation cluster for Flanders.
Picture of BioVox

BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is powered by Biovia: the health innovation cluster for Flanders.

Novartis takes license on Celyad’s allogeneic CAR T cells

Yet another phase 2 filgotinib study for Galapagos: cutaneous lupus erythematosus

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematosus.

Kiadis Pharma files EMA marketing authorization for ATIR101™ in blood cancers

Kiadis Pharma asks permission to the EMA to bring its lead product to the market. ATIR101™ protects blood cancer patients receiving a stem cell transplant from vulnerability to infections and disease relapse.

Characterising the profile of metastatic breast cancer for improved treatment

How Europe responds to the demise of the fire salamander

Galapagos raises $338 million gross proceeds in a US public offering

Reversed Brexit: £250 million for Bart De Strooper’s dementia research

Macrophages to protect you from asthma

It has long been known that exposure to microbes can play a protective role against the subsequent development of asthma. Researchers from GIGA of the University of Liège provide an explanation and propose to use this discovery to set up a strategy of cell therapy to treat asthma in humans. Their discovery is published in Immunity.

MyCartis barcodes biological samples

CMAST: Bringing ideas from a risky early stage to a viable healthcare solution

argenx receives first preclinical milestone payment in AbbVie collaboration

ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from development partner AbbVie.

Epilog Launches EEG Analysis Tool

argenx launches Phase II study for cutaneous T-cell lymphoma therapy

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relapsed/refractory cutaneous T-cell lymphoma (CTCL).

Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer versus PSA testing alone, leading to a reduction in total cost per patient and a quality of life improvement.

Galapagos doses first psoriatic arthritis patient with filgotinib

First dosing triggers $10 million milestone payment from Gilead